869640-48-2

Usage

Uses

Used in Pharmaceutical Industry:
N-methyl 2-bromo-5-pyridinecarboxamide is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, N-methyl 2-bromo-5-pyridinecarboxamide is employed as an intermediate in the production of agrochemicals, aiding in the creation of compounds that can enhance crop protection and yield.
Used in Organic Synthesis:
N-methyl 2-bromo-5-pyridinecarboxamide is utilized as a versatile building block in organic synthesis, enabling the formation of a wide range of organic compounds for various applications across different industries.
Used in Research and Development:
N-methyl 2-bromo-5-pyridinecarboxamide is also used by researchers and scientists as a fundamental component in the development of new compounds, driving innovation and advancement in the chemical industry.

Upstream product

• 6311-35-9 6-bromonicotinic acid 
• 593-51-1 methylamine hydrochloride 
• 74-89-5 methylamine 

Downstream Products

• 1610611-56-7 N-(4-cyanophenyl)-N-cyclopropyl-3-(5-(methylcarbamoyl)pyridin-2-yl)pyrazolo[1,5-a]pyridine-5-carboxamide 

Relevant academic research and scientific papers

CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands

The invention relates to tetrahydronaphthyridine derivatives having formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said tetrahydronaphthyridine derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.